Notices. Notice

5,194 words·~24 min read·/register/2007/05/02/07-2144

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4184-01-M DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Statement of Organization, Functions and Delegation of Authority Notice is hereby given that I have delegated to the Commissioner, Administration on Children, Youth and Families, the following authority vested in me by the Secretary of Health and Human Services in memoranda dated August 20, 1991, Delegations of Authority for the Runaway and Homeless Youth Program, Drug Abuse Education and Prevention Programs Relating to Youth Gangs, and Runaways and Homeless Youth;

August 20, 1991, Delegation of Authority for Family Violence Prevention and Services Program; August 20, 1991, Delegations of Authority for Social Security Act Programs; June 9, 2004, Delegation of Authority for the Abstinence Education Program under Title V, section 510 of the Social Security Act, as amended; and May 31, 2005, Delegation of Authority for the Abstinence Education Program, under Title V, Section 501(a)(2) of the Social Security Act, as amended.

(a)Authorities Delegated 1. Authority to administer the Runaway and Homeless Youth Program under the Runaway and Homeless Youth Act, 42 U.S.C. 5701, *et seq.* , and as amended, now and hereafter. 2. Authority to administer the Drug Abuse Education and Prevention Program Relating to Youth Gangs under Sections 3501-3505 of the Anti-Drug Abuse Act of 1988, 42 U.S.C. 11801-11805, and as amended, now and hereafter. 3. Authority to administer the Drug Abuse Education and Prevention Program Relating to Runaways and Homeless Youth under Sections 3511-3515 of the Anti-Drug Abuse Act of 1988, 42 U.S.C. 11821-11825, and as amended, now and hereafter. 4. Authority to administer provisions of the Family Violence Prevention and Services Act, 42 U.S.C. 10401, *et seq.* , and as amended, now and hereafter. 5. Authority to administer the provisions of section 439 of the Social Security Act, 42 U.S.C. 629i, concerning Grants for Programs for Mentoring Children of Prisoners, and as amended, now and hereafter. 6. Authority to administer the Abstinence Education Program under section 510 of the Social Security Act, 42 U.S.C. 710, and as amended, now and hereafter. 7. Authority to continue the administration of grants and contracts initially awarded in Fiscal Years 2002, 2003 and 2004 under the Special Projects of Regional and National Significance (SPRANS) Community-based Abstinence Education Program, pursuant to Title V, Section 501(a)(2) of the Social Security Act, as amended. The SPRANS Community-based Abstinence Education Program includes Community-based Abstinence Education grants, Abstinence Education Special Congressional Initiative Project grants, and the Abstinence Education Technical Assistance contract with the National Abstinence Clearinghouse. This delegation permits the Commissioner to administer the Fiscal Years 2002, 2003 and 2004 SPRANS abstinence education grants under the terms and conditions of the initial awards, thereby allowing the continuation of the existing grants consistent with recent appropriations enactments (Pub. L. 108-447).

(b)Limitations 1. These delegations shall be exercised under the Department's existing policies on delegations and regulations. 2. This delegation excludes the authority to submit reports to Congress and shall be exercised under financial and administrative requirements applicable to all Administration for Children and Families' authorities. 3. The approval or disapproval of grant applications and the making of grant awards requires concurrence of the appropriate Grants Officer. The approval or disapproval of contract proposals and awards is subject to the requirements of the Federal Acquisition Regulations and requires the concurrence of the Contracting Officer. 4. This delegation of authority does not include the authority to sign and issue notices of grant awards. 5. This authority does not include the authority to appoint Action Officials for Audit Resolution. 6. This delegation of authority does not include the authority to appoint Central Office or Regional Office Grant Officers for the administration of Family and Youth Services programs. 7. This delegation of authority does not include the authority to administer the Demonstration Grants for Community Initiatives, 42 U.S.C. 10418, under the Family Violence Prevention and Services Act. 8. Responsibilities under the Family Violence Prevention and Services Act are to be carried out in accordance with the requirements of Section 307, 42 U.S.C. 10406. This delegation of authority does not include enforcement authority under Section 307. 9. Any employee of the Department of Health and Human Services who is appointed to carry out one or more provisions of the Family Violence Prevention and Services Act shall, prior to such appointment, have had expertise in the field of family violence prevention and services. 10. Any redelegation shall be in writing and prompt notification must be provided to all affected managers, supervisors and other personnel and requires the concurrence of the Deputy Assistant Secretary for Administration.

(c)Effect on Existing Delegations This delegation supersedes all previous delegations of authority involving the authorities delegated herein.

(d)Effective Date This delegation is effective upon the date of signature. I hereby affirm and ratify any actions taken by the Commissioner, Administration on Children, Youth and Families, which involved the exercise of the authorities delegated herein prior to the effective date of this delegation. Dated: April 19, 2007. Daniel C. Schneider, Acting Assistant Secretary for Children and Families. [FR Doc. E7-8321 Filed 5-1-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Statement of Organization, Functions, and Delegations of Authority This notice amends Part K of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (DHHS), Administration for Children and Families (ACF), as follows: Chapter KB, the Administration on Children, Youth and Families (ACYF), as last amended May 23, 2006, 71 FR 29649, and October 6, 2006, 71 FR 59117. This notice reflects realignment of the Family Violence Prevention and Services Program from the Division of State Assistance, Office of Community Services, to the Family and Youth Services Bureau, ACYF. This notice also reflects the reassignment of certain Abstinence Education activities from the Maternal and Child Health Bureau, Health Resources Services Administration (HRSA), to the Family and Youth Services Bureau, ACYF. In addition, this notice establishes three divisions under the Family and Youth Services Bureau. Chapter KB is amended as follows: Chapter KB, Administration on Children, Youth and Families A. Delete the last sentence of KB.00 Mission and replace the last sentence with the following: It administers Child Welfare Services training and Child Welfare Services research and demonstration programs authorized by title IV-B of the Social Security Act; administers programs under the Runaway and Homeless Youth Act; administers abstinence education grants under section 510 of the Social Security Act and other abstinence education programs; carries out provisions of the Family Violence Prevention and Services Act, administers the program for mentoring children of prisoners under section 439 of the Social Security Act; and manages initiatives to involve the private and voluntary sectors in the areas of children, youth and families. B. Delete KB.10 Organization in its entirety and replace with the following: KB.10 Organization. The Administration on Children, Youth and Families is headed by a Commissioner, who reports directly to the Assistant Secretary for Children and Families and consists of: • Office of the Commissioner

(KBA)• Office of Management Services

(KBA1)• Program Operations Division

(KBC1)• Program Support Division

(KBC2)• Program Management Division

(KBC3)• Children's Bureau

(KBD)• Children's Bureau Regional Units (KBDDI-X) • Office of Child Abuse and Neglect

(KBD1)• Division of Policy

(KBD2)• Division of Program Implementation

(KBD3)• Division of Data, Research and Innovation

(KBD4)• Division of Child Welfare Capacity Building

(KBD5)• Division of State Systems

(KBD6)• Family and Youth Services Bureau

(KBE)• Division of Youth Services

(KBE1)• Division of Family Violence Prevention

(KBE2)• Division of Abstinence Programs

(KBE3)• Immediate Office/Administration

(KBG1)• Program Operations Division

(KBG2)• Policy Division

(KBG3)• Technical Assistance Division

(KBG4)C. Delete KB.20 Functions, Paragraph E, in its entirety and replace with the following: KB.20 Functions. E. The Family and Youth Services Bureau is headed by an Associate Commissioner who recommends policy direction and programs to address issues involving youth, family, abstinence education, mentoring children of prisoners, and domestic violence issues to the Commissioner, ACYF. The Associate Commissioner has a Deputy Associate Commissioner who acts as his alter ego and is responsible for the day-to-day direction of three divisions. The Office of the Associate Commissioner also has a Research, Data and Evaluation Team and a Regional Operations Team. The Bureau assesses policies, legislation and programs that affect runaway and homeless youth, families, mentoring children of prisoners, domestic violence and abstinence education. It recommends budgetary and legislative proposals and subject areas for research and demonstration activities; coordinates efforts with and provides expert advice to departmental and other federal agencies on youth issues and programs including runaway and homeless youth and youth at risk of involvement with gangs, violence and drugs and other youth in at-risk situations; and develops program initiatives to address abstinence education and the needs of runaway and homeless youth, families, children of prisoners and domestic violence victims and their dependents. The Bureau represents HHS on various councils, workgroups and committees and provides leadership and coordination to other HHS programs and agencies. The Bureau has the following divisions: 1. The Division of Youth Services promotes a youth development approach to program services so that Bureau programs and activities are planned and designed with an emphasis on meeting the developmental needs of young people and their families, including runaway and homeless youth, youth at risk of involvement with gangs, violence and drugs and other youth in at-risk situations. The Division's administration of the runaway and homeless youth program—which incorporates the basic center, street outreach and transitional living programs—includes development and implementation of policy, guidelines and regulations concerning the funding and management of service projects for youth under the Runaway and Homeless Youth Act. Administration of the program for mentoring children of prisoners authorized under section 439 of the Social Security Act also includes development of policy, guidelines and regulations regarding the funding and management of grant projects and other activities. The Division oversees the receipt and review of applications for grants that ultimately provide services to youth and families and monitors the management of these grants in the ACF Regional Offices. In addition, the Division designs, develops, funds and monitors support activities related to these programs, including, but not limited to, the provision of technical assistance, a monitoring system, a data collection system, a family and youth clearinghouse and a national communications system/hotline. The Division determines the conceptual and policy framework to address issues facing families and adolescents. It identities problems, defines critical issues for investigation and makes recommendations regarding subject areas for research, demonstration and evaluation activities. Based on the outcomes of these activities, the Division disseminates information through conferences, forums and written materials; provides assistance to service providers and state and local governments in planning, developing, implementing and evaluating programs affecting family and youth; and recommends plans and programs to increase public awareness and understanding about activities affecting vulnerable families and youth. 2. The Division of Family Violence Prevention promotes public awareness about domestic violence and its impact. The Division's programs support the prevention of family violence; provide immediate shelter and related assistance to victims of family violence and their dependents; provide for research into the most effective prevention, identification and treatment of family violence; and provide training and technical assistance to family violence personnel in states, tribes, local public agencies (including law enforcement agencies, courts, social service agencies and health care professionals) and non-profit organizations. The Division is responsible for developing, updating and implementing program regulations and policies. The Division oversees the receipt and review of applications for grants and certain grantee activities. It also provides guidance, review, support and assistance to states and grantees on HHS policies, regulations, procedures and systems necessary to ensure efficient program operation at the state, territorial and tribal levels. In addition, the Division coordinates all programs within the Department of Health and Human Services, and seeks to coordinate all other Federal programs, which involve the prevention of incidents of family violence and the provision of assistance for victims and potential victims of family violence and their dependents. 3. The Division of Abstinence Programs manages the Abstinence Education State Grant Program, which provides formula grants to states and other jurisdictions for the purpose of providing abstinence education as defined by Section 510 of the Social Security Act. The Division also manages the Community-Based Abstinence Education Grant Program, which makes competitive grants to public and private entities to plan and implement strategies for providing abstinence education to adolescents. The Division develops the conceptual framework to address abstinence education issues, monitors and assesses the programs and ensures the provision of technical assistance. Dated: April 19, 2007. Daniel C. Schneider, Acting Assistant Secretary for Children and Families. [FR Doc. E7-8318 Filed 5-1-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Statement of Organization, Functions and Delegation of Authority Notice is hereby given that I have delegated to the Principal Deputy Assistant Secretary, Deputy Assistant Secretaries, Program Directors, Program Commissioners, Deputy Director/Commissioner, Office of Child Support Enforcement, and Staff Office Directors the following authority vested in me by the Secretary of Health and Human Services in the memorandum dated August 20, 1991, Delegations of Authority for Social Security Act Programs; 31 U.S.C. 1535; and HHS General Administrative Manual, Chapter 8-77.

(a)Authorities Delegated. 1. Authority to administer approved cooperative research experimental, pilot or demonstration projects under the provisions of sections 1110 and 1115 of the Social Security Act. 2. Authority to approve interagency agreements to procure, provide or exchange services, supplies or equipment.

(b)Limitations. 1. The authority listed in #1 above shall be exercised under the condition that projects may be administered by the Office of Planning, Research and Evaluation (OPRE), by the program/staff office or jointly by OPRE with the program/staff office. 2. Where all or any part of an experimental, pilot, research or demonstration project is wholly financed with Federal funds made available under sections 455(e), 1110 or 1115 of the Social Security Act, without any State, local or other non-Federal financial participation, that project must be approved by the Secretary of Health and Human Services. 3. This delegation of authority does not include the authority to approve/disapprove projects under sections 1110 or 1115 of the Social Security Act or approve/disapprove waivers of State Plan requirements or costs that would not otherwise be included as expenditures under the provisions of section 1115(a)(1) and

(2)of the Social Security Act. 4. The authority to approve interagency agreements to procure, provide, or exchange services, supplies, or equipment requires the concurrence of the ACF Chief Financial Officer if it exceeds $250,000 (including amendments) within a fiscal year or if it requires the signature of the Assistant Secretary, ACF, or the Secretary of HHS.

(c)Effect on Existing Delegations. As related to this delegation of authority, this delegation supersedes all previous delegations of authority involving the administration of the cross-program authorities delegated herein.

(d)Effective Date. This delegation is effective upon the date of signature. I hereby ratify and affirm any actions taken by the Principal Deputy Assistant Secretary, Deputy Assistant Secretaries, Program Directors, Program Commissioners, Deputy Director/Commissioner, Office of Child Support Enforcement, and Staff Office Directors, which involved the exercise of the authority delegated herein prior to the effective date of this delegation. Dated: April 19, 2007. Daniel C. Schneider, Acting Assistant Secretary for Children and Families. [FR Doc. E7-8319 Filed 5-1-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2007D-0135] Guidance for Industry on Testing of Glycerin for Diethylene Glycol; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing the availability of a guidance for industry entitled “Testing of Glycerin for Diethylene Glycol.” This guidance provides recommendations on testing that will help pharmaceutical manufacturers, repackers, and other suppliers of glycerin, and pharmacists who engage in drug compounding, avoid the use of glycerin that is contaminated with diethylene glycol

(DEG)and prevent incidents of DEG poisoning. DATES: Submit written or electronic comments on the guidance by July 31, 2007. General comments on agency guidance documents are welcome at any time. ADDRESSES: Submit written requests for single copies of the guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. FOR FURTHER INFORMATION CONTACT: Monica Caphart, Center for Drug Evaluation and Research (HFD-320), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857,301-827-9047. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a guidance for industry entitled “Testing of Glycerin for Diethylene Glycol.” This guidance explains that the agency recommends that certain analytical testing procedures be performed on glycerin to avoid the use of DEG-contaminated product. Specifically, the agency is recommending that all lots of glycerin received by a pharmaceutical manufacturing facility undergo identity testing that includes a test for DEG content. DEG contamination of glycerin can be detected by using specific analytical test procedures described in the United States Pharmacopeia monograph for glycerin, which quantifies the amount of DEG present at a detection level of 0.1 percent, as recommended by the interagency Diethylene Glycol Contamination Prevention Workshop of 1997. Repackers, pharmacy compounders, and others who distribute and prepare glycerin for use in drug products should test glycerin that is used, sold for use, or intended for use in drug products. This recommendation also applies to bulk or repackaged glycerin intended as an excipient or other component for a drug. In addition, pharmacies that purchase glycerin for use in compounding drug products should either test the glycerin or ensure that such testing was properly done by a reliable supplier. As explained in detail in the guidance, there have been repeated instances of DEG poisoning that have led to the development of this guidance. Between 1990 and 1998, DEG poisoning has been reported in Haiti, Argentina, Bangladesh, India, and Nigeria. More recently, in October 2006, there were cases of illness and death in Panama due to DEG poisoning. The cases involving DEG contamination reveal the following similarities: • The pharmaceutical manufacturers did not perform full identity testing on the glycerin raw material, including tests to quantify the amount of DEG present and to verify the purity of the glycerin received. • The pharmaceutical manufacturers of the contaminated products relied on the certificate of analysis

(COA)provided by the supplier. • The origin of the product was not easily apparent from the COA. FDA has no reason to believe that the U.S. supply of glycerin is affected at the present time. However, because of the serious nature of this potentially fatal problem and the global nature of the pharmaceutical supply chain, FDA is emphasizing in this guidance the importance of testing glycerin for DEG. We are issuing this level 1 guidance for immediate implementation, consistent with FDA's good guidance practices regulation (21 CFR 10.115). The agency is not seeking comment prior to implementing this guidance because of the potential for a serious public health impact if DEG-contaminated glycerin were to enter the domestic market. The guidance represents the agency's current thinking on this issue. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments on the guidance. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. III. Electronic Access Persons with access to the Internet may obtain the document at either *http://www.fda.gov/cder/guidance/index.htm* or *http://www.fda.gov/ohrms/dockets/default.htm* . Dated: April 16, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7-8389 Filed 5-1-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Health Resources and Services Administration

(HRSA)publishes abstracts of information collection requests under review by the Office of Management and Budget (OMB), in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on

(301)443-1129. The following request has been submitted to the OMB for review under the Paperwork Reduction Act of 1995: Proposed Project: Bureau of Primary Health Care

(BPHC)Uniform Data System (OMB No. 0915-0193)—Extension for 2007 UDS Data Collection The Uniform Data System

(UDS)contains the annual reporting requirements for the cluster of primary care grantees funded by HRSA. The UDS includes reporting requirements for grantees of the following primary care programs: Community Health Centers, Migrant Health Centers, Health Care for the Homeless, Public Housing Primary Care, and other grantees under Section 330. The authorizing statute is Section 330 of the Public Health Service Act, as amended. HRSA collects data in the UDS which is used to ensure compliance with legislative mandates and to report to Congress and policy makers on program accomplishments. To meet these objectives, HRSA requires a core set of data collected annually that is appropriate for monitoring and evaluating performance and reporting on annual trends. Estimates of annualized reporting burden are as follows: Type of report Number of respondents Responses per respondent Total responses Hours per response Total burden hours Universal Report 1,055 1 1,055 28 29,540 Grant Report 145 1 145 18 2,610 Total 1,055 1,100 32,150 Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Karen Matsuoka, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503. Dated: April 25, 2007. Caroline Lewis, Acting Associate Administrator for Administration and Financial Management. [FR Doc. E7-8379 Filed 5-1-07; 8:45 am] BILLING CODE 4165-15-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Diagnosing and Treating Cancer Using Beta-Catenin Splice Variants *Description of Technology:* This application discloses and claims inventions which may be used alone or together. One group of inventions relates to early detection diagnostic, prognostic and patient monitoring methods (“Diagnostic Methods”). The other group of inventions relates to methods of treatment. Both groups of inventions have particular application with respect to esophageal squamous cell cancers

(ESCC)or other types of adenocarcinomas and squamous cell carcinomas. The Diagnostic Methods are useful in evaluating the status of preneoplastic lesions as well as tumor tissue. Because of this, the methods can be used to track the progression or regression of disease in many types of cell samples from normal to dysplasia to cancer. The Diagnostic Methods involve measuring the level of one or more pairs of transcripts or the protein products of these pairs of transcripts or the cellular localization of the transcripts or proteins. The primary transcripts or protein products useful in this method are those of the beta-Catenin gene (CTNNB1). In particular, the levels of the 16A and 16B CTNNB1 transcripts or protein products are of importance in carrying out the methods of this patent application. Other gene transcripts or protein products that may be used in conjunction with CTNNB1 16A and 16B to provide additional information are WAF1

(p21)and cMYC. The treatment methods include employing small interfering RNA molecules (siRNAs) as a means to alter the expression of one or more of these particular CTNNB1 transcripts. More specifically, preferred siRNA molecules can be used to alter the expression of the CTNNB1 transcripts 16A and/or 16B. These siRNA molecules may be single-stranded

(ss)or double-stranded

(ds)and may be delivered using a construct capable of producing the siRNA molecule upon delivery to the target cell. *Applications:* Diagnostic or prognostic methods for squamous cell cancers and adenocarcinomas; Monitoring therapeutic response during and after patient treatment; Development of cancer treatments; Basic research to further elucidate the role of beta catenin in signal transduction pathways and carcinogenesis. *Development Stage:* The use of beta catenin transcripts to provide prognostic or diagnostic information remains the subject of research but early patient data is found in the article in Genes Chromosomes & Cancer listed below. Work related to the use of siRNA as a treatment strategy remains in its early stages of research and has not yet progressed to clinical trials. *Inventors:* Mark J. Roth and Konrad Huppi (NCI). *Publications:* 1. The patent application has been published as WO 2006/086772 A2 on 17 August 2006. 2. MJ Roth *et al.* beta-Catenin splice variants and downstream targets as markers for neoplastic progression of esophageal cancer. Genes Chromosomes Cancer. 2005 Dec;44(4):423-428. 3. SE Martin *et al.* Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res. 2007 Mar 28; E published ahead of print, doi:10.1093/nar/gkm141. 4. A Thiele *et al.* AU-rich elements and alternative splicing in the beta-Catenin 3' UTR can influence the human beta-Catenin mRNA stability. Exp Cell Res. 2006 Jul;312:2367-2378. *Patent Status:* PCT/US2006/05032 filed 10 Feb 2006 and published as WO 2006/086772 on 17 Aug 2006, currently pending, entitled “Method of Diagnosing and Treating Cancer Using Beta Catenin Splice Variants” (HHS Reference No. E-018-2005/2-PCT-01); U.S. Provisional Application No. 60/667,084 filed 30 Mar 2005, now abandoned (HHS Reference No. E-018-2005/1-US-01); U.S. Provisional Application No. 60/652,154 filed 10 Feb 2005, now abandoned (HHS Reference No. E-018-2005/0-US-01). *Biological Materials Availability:* Biological materials related to this technology are available and include those referred to in the following publications as well as a series of recently established aptamers capable of specific binding to the CTNNB1 protein. 1. MJ Roth *et al.* Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. Cancer. 1997 Dec 1;80(11):2047-2059. 2. Q-J Pan *et al.* Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Linxian, China. ACTA Cytologica (In Press). 3. MJ Roth *et al.* A study of beta-catenin splice variants and associated downstream targets as markers for neoplastic progression of squamous cell carcinoma of the esophagus. Genes Chromosomes Cancer. 2005 Dec;44(4):423-428. 4. PJ Limburg *et al.* Randomized, placebo-controlled esphogeal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005 Sept;129(3):863-873. *Licensing Availability:* This application is available for license on a non-exclusive or exclusive basis. *Licensing Contact:* Susan S. Rucker, Esq.; 301/435-4478; *ruckersu@mail.nih.gov* *Collaborative Research Opportunity:* The National Cancer Institute, Division of Cancer Epidemiology and Genetics, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method of diagnosing and treating cancer using beta-Catenin splice variants. Please contact John D. Hewes, PhD at 301-435-3121 or *hewesj@mail.nih.gov* for more information. 8356 Dated: April 25, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7-8356 Filed 5-1-07; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Fogarty International Center; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Fogarty International Center Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* Fogarty International Center Advisory Board. *Date:* May 21-22, 2007. *Closed:* May 21, 2007, 1 p.m. to 5 p.m. *Agenda:* To review and evaluate grant applications and/or proposals. *Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892. *Open:* May 22, 2007, 8:30 a.m. to 5 p.m. *Agenda:* Fogarty International Center will present an early draft of the Strategic Plan. *Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892. *Contact Person:* Jean L. Flagg-Newton, Ph.D., Special Assistant to the Director, FIC, Fogarty International Center, National Institutes of Health, 9000 Rockville Pike, Building 31, Room B2C29, Bethesda, MD 20892,

(301)496-2968, *flaggnej@mail.nih.gov* . Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. Information is also available on the Institute's/Center's home page: *http://www.nih.gov/fic/about/advisory.html,* where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.106, Minority International Research Training Grant in the Biomedical and Behavioral Sciences; 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome; 93.168, International Cooperative Biodiversity Groups Program; 93.934, Fogarty International Research Collaboration Award; 93.989, Senior International Fellowship Awards Program, National Institutes of Health, HHS) Dated: April 24, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07-2144 Filed 5-1-07; 8:45 am]

Connectionstraces to 8

Traces to 8 documents

U.S. Code